Asset Management Ventures

Asset Management Ventures, established in 1965, is a Palo Alto-based venture capital firm specializing in early-stage investments. The company focuses on digital health, tech, and life sciences sectors, with a track record of backing innovative companies such as Amgen. It operates across Asia-Pacific and North America, providing capital and expertise to fuel growth and innovation in its portfolio companies.

Jialu Chen

Principal

Skip Fleshman

Managing Partner

Kevin Ho

Associate

Alison Jahansouz

Analyst

Louis Lange

Partner

Lou Lange

Partner

Martin Shapiro

Principal

rich simoni

Managing Partner

150 past transactions

SeeQC

Series A in 2025
SeeQC, Inc. is a semiconductor company specializing in the development of a digital quantum computing platform aimed at global businesses. Founded in 2018 and headquartered in Elmsford, New York, the company designs, tests, and manufactures quantum-ready superconductors and application-specific quantum computing systems. Its innovative approach combines classical and quantum technologies to enhance the efficiency, stability, and cost-effectiveness of quantum computing systems. SeeQC integrates superconducting qubit chips, proprietary Single Flux Quantum technology, and application-specific integrated circuits to create a commercially viable quantum computing solution. The company serves various industries, including machine learning, logistics optimization, quantum chemistry, pharmaceuticals, and fintech, catering to clients in the United States and Europe. With additional facilities in London and Naples, SeeQC aims to facilitate access to scalable, fault-tolerant quantum computing applications, thereby addressing the growing demand for advanced computational capabilities.

Medsien

Convertible Note in 2024
Medsien is a provider of remote care management services that utilizes artificial intelligence to enhance patient engagement and health outcomes. The company has developed a platform that integrates various care management programs, allowing healthcare providers to efficiently monitor chronic conditions and manage remote patient care. By curating and aggregating patient data, Medsien's technology delivers insights into patient health trends and metrics, enabling real-time notifications of any changes. This streamlined approach not only improves the patient experience but also helps reduce costs and supports informed decision-making for healthcare providers.

Endless Health

Seed Round in 2024
Endless Health is a digital platform dedicated to cardiovascular health management. It offers evidence-based information on heart conditions and prevention strategies, along with remote consultations via video chat or messaging with certified healthcare professionals. Users can track their health data and goals through an intuitive dashboard.

Basys.ai

Pre Seed Round in 2023
Basys.ai streamlines healthcare administration by automating prior authorization and utilization management processes for health plans using an AI-based platform. This proprietary system digitizes payer policies via machine learning, reducing implementation timelines significantly.

Autonomize

Venture Round in 2023
Autonomize AI is a leader in the AI-driven healthcare sector, dedicated to transforming the industry through the development of advanced AI copilots. These copilots are designed to organize, contextualize, and summarize unstructured data, thereby alleviating the administrative burdens faced by healthcare knowledge workers. This functionality allows professionals to make swift, data-driven decisions that enhance patient outcomes. Autonomize AI's solutions encompass various applications, including clinical trials, target discovery, drug toxicity, commercial intelligence, and patient journeys, enabling healthcare professionals to efficiently extract contextual information from diverse healthcare data sources. As a founding member of CancerX, part of the US President Biden's Cancer Moonshot initiative, the company is committed to innovation in cancer research and treatment. Its clientele includes top pharmaceutical companies, major payors, and leading firms in life sciences, reflecting its significant impact on the healthcare landscape through the use of natural language processing, machine learning, and advanced data analytics.

SubjectWell

Series B in 2022
SubjectWell is a clinical trial marketplace focused on patient recruitment, providing a risk-free platform for healthcare clients to efficiently find and screen qualified participants for clinical trials. By streamlining the recruitment process, SubjectWell helps accelerate the completion of studies, ensuring that healthcare organizations can meet their research timelines effectively. The company specializes in delivering highly qualified referrals, thereby enhancing the overall efficiency of clinical trials and contributing to advancements in medical research.

Array Insights

Venture Round in 2022
Array Insights is an IT firm focused on developing artificial intelligence-driven solutions aimed at managing patient and caregiver narratives. The company offers a clinical data registry platform that enables the secure sharing of sensitive healthcare data while maintaining ownership and compliance. By employing advanced encryption techniques, Array Insights connects data algorithms to facilitate the analysis and training of AI models without compromising security or privacy. This platform allows hospitals and healthcare providers to effectively control, track, and trace patient information, thereby enhancing research capabilities and accelerating the pace of innovation in the healthcare sector. Founded in 2017 and based in Cambridge, Massachusetts, Array Insights is dedicated to improving data accessibility while safeguarding proprietary and sensitive information.

Carta Healthcare

Series B in 2022
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.

LegalMate

Seed Round in 2022
LegalMate is a business focused on improving access to legal services for individuals, particularly those from low-income backgrounds. Recognizing that a significant number of civil legal problems go unresolved due to inadequate representation, LegalMate offers a financing solution that allows law firms to receive their fees upfront, while adhering to regulatory guidelines. This model not only alleviates the financial burden on clients but also empowers them to seek legal assistance on their own terms. In addition to its financing services, LegalMate has developed a legal automation platform designed to streamline workflow and tailor solutions to the specific needs of clients. By automating complex legal processes, the platform enhances efficiency for law firms and legal professionals, enabling them to devote more time to delivering high-quality legal services.

Pluto Health

Seed Round in 2022
Pluto Health is a technology company that builds a care coordination platform for patients and providers. The platform aggregates electronic health record data from multiple health systems, pharmacies, and laboratories, and automatically extracts insights to support personalized care plans. It offers remote monitoring tools, communication channels between patients and clinicians, and reminders for tasks such as medication adherence, bill payments, and data sharing. By integrating diverse health data and providing proactive coordination, the platform helps patients fill care gaps and access tailored clinical support.

Outcomes4Me

Series A in 2021
Founded in 2017, Outcomes4Me is a Boston-based company that empowers cancer patients through its AI-driven platform. This platform provides personalized, evidence-based treatment options and real-time clinical information, enabling patients to navigate their care effectively and improve outcomes.

Carta Healthcare

Series A in 2021
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.

Array Insights

Seed Round in 2020
Array Insights is an IT firm focused on developing artificial intelligence-driven solutions aimed at managing patient and caregiver narratives. The company offers a clinical data registry platform that enables the secure sharing of sensitive healthcare data while maintaining ownership and compliance. By employing advanced encryption techniques, Array Insights connects data algorithms to facilitate the analysis and training of AI models without compromising security or privacy. This platform allows hospitals and healthcare providers to effectively control, track, and trace patient information, thereby enhancing research capabilities and accelerating the pace of innovation in the healthcare sector. Founded in 2017 and based in Cambridge, Massachusetts, Array Insights is dedicated to improving data accessibility while safeguarding proprietary and sensitive information.

Outcomes4Me

Seed Round in 2020
Founded in 2017, Outcomes4Me is a Boston-based company that empowers cancer patients through its AI-driven platform. This platform provides personalized, evidence-based treatment options and real-time clinical information, enabling patients to navigate their care effectively and improve outcomes.

Lark

Series C in 2020
Lark is a developer of a virtual platform focused on chronic disease prevention and management. Founded in 2011 by Julia Hu and Jeff Zira, the company is headquartered in Mountain View, California. Lark's platform leverages advanced artificial intelligence alongside human coaching and connected devices to offer real-time, personalized support and counseling. This approach aims to help users make healthier choices and effectively manage their chronic conditions. The company's programs, including those recognized by the CDC for diabetes prevention, wellness, diabetes care, and hypertension, serve approximately 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in multiple peer-reviewed journals and analyst reports.

Reify Health

Series B in 2020
Reify Health, Inc. is a Baltimore-based company that specializes in cloud-based software aimed at enhancing the development of new therapies within the life sciences sector. Founded in 2010, Reify Health provides solutions designed to streamline clinical research processes, particularly in the area of patient enrollment for clinical trials. Its flagship product, StudyTeam, allows research sponsors, contract research organizations, and clinical sites to achieve faster and more predictable enrollment outcomes. By automating and simplifying the enrollment process, Reify Health's software enables teams to concentrate on essential tasks that drive research success, thereby improving overall productivity and optimizing study budgets.

Unnatural Products

Seed Round in 2019
Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, focused on drug discovery through innovative technology. Founded in 2016, the company specializes in designing and developing a platform that utilizes artificial intelligence and computational biology techniques to create macrocyclic peptides. These peptides target intracellular protein interactions, addressing drug targets that are typically considered undruggable. By harnessing machine learning to optimize chemical synthesis, Unnatural Products aims to accelerate the drug discovery process, offering potential therapeutic strategies for a wide range of medical conditions. Through its unique approach, the company seeks to pioneer new treatments where traditional methods have fallen short.

Aegis Surgical

Convertible Note in 2019
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

Arterys

Convertible Note in 2019
Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

UniKey Technologies

Convertible Note in 2019
UniKey Technologies specializes in smart access control solutions. It offers a mobile platform that replaces traditional keys with smartphone-based electronic keys, featuring touch-to-open technology, intelligent detection of user location, and robust security measures. The company partners with lock manufacturers like Kwikset and Weiser to create smart locks such as Kevo, and provides cloud-based lock management for multifamily properties and commercial businesses.

Welkin Health

Series B in 2019
Founded in 2013, Welkin Health develops software that guides healthcare teams through patient management workflows. Its platform ensures patients receive care at the right time by configuring care programs into actionable tasks for health workers. Welkin's software facilitates communication between providers, health plans, and patients via phone, text, video, and email.

Mightier

Series A in 2019
Mightier is a Boston-based company that develops bioresponsive video games and a family program designed to help children regulate emotions. The platform pairs gameplay with a biofeedback heart rate monitor to adjust game difficulty, encouraging kids to stay calm and in control while learning to recognize and manage emotions in daily life. Created through collaboration with Boston Children's Hospital and Harvard Medical School, Mightier aims to address behavioral and emotional challenges by teaching real-time emotion regulation skills. Founded in 2016, the company offers a program that integrates mind-body signals into interactive experiences, enabling children to practice emotional control through engaging, age-appropriate games.

Signal Vine

Convertible Note in 2019
Signal Vine, Inc. is a technology company that specializes in developing an enterprise text messaging platform designed to enhance communication within educational and nonprofit sectors. Founded in 2013 and headquartered in Alexandria, Virginia, the company offers a range of features including targeted messaging, an intuitive interface, case management, and comprehensive reporting and analytics. By utilizing a blended messaging approach, Signal Vine enables its clients—such as K-12 schools, higher education institutions, nonprofits, and government programs—to leverage student data to deliver personalized communications. This capability aims to improve student engagement by sending timely reminders and support messages about important deadlines and opportunities, ultimately fostering better enrollment and retention outcomes. Additionally, Signal Vine provides customer support services to assist users in maximizing the effectiveness of their messaging strategies.

Carta Healthcare

Convertible Note in 2019
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.

InCarda Therapeutics

Series B in 2018
InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Properly

Series A in 2018
Properly, Inc. is a technology company based in San Francisco, California, established in 2014. It offers a platform and mobile application designed to streamline operations related to vacation rental properties, including housekeeping and property maintenance. Properly serves a diverse clientele, including property owners, property managers, and service providers. The company's visual checklist tool facilitates effective communication between property owners and cleaning professionals, ensuring that turnover instructions are easily shared and understood. Properly aims to standardize the cleaning process for hosts and property managers while enhancing the recognition of professional cleaners for their quality work.

Aegis Surgical

Convertible Note in 2017
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

3T Biosciences

Seed Round in 2017
Founded in 2017, 3T Biosciences is a biotechnology company based in Menlo Park, California. It specializes in immunotherapies for cancer treatment.

Huiseoul

Seed Round in 2017
Huiseoul is an e-commerce company based in Seoul, South Korea, specializing in the online retail of cosmetic products. It focuses on providing personalized skincare consultations and exclusively offers Korean beauty products to the Chinese market. The company has developed a comprehensive online platform that facilitates conversational e-commerce, where beauty consultants deliver detailed skincare advice in a user-friendly format. This platform includes various technological components such as front-end and back-end development, API integration, and mobile applications, all aimed at enhancing the customer experience in skincare shopping.

Freenome

Series A in 2017
Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Signal Vine

Series A in 2017
Signal Vine, Inc. is a technology company that specializes in developing an enterprise text messaging platform designed to enhance communication within educational and nonprofit sectors. Founded in 2013 and headquartered in Alexandria, Virginia, the company offers a range of features including targeted messaging, an intuitive interface, case management, and comprehensive reporting and analytics. By utilizing a blended messaging approach, Signal Vine enables its clients—such as K-12 schools, higher education institutions, nonprofits, and government programs—to leverage student data to deliver personalized communications. This capability aims to improve student engagement by sending timely reminders and support messages about important deadlines and opportunities, ultimately fostering better enrollment and retention outcomes. Additionally, Signal Vine provides customer support services to assist users in maximizing the effectiveness of their messaging strategies.

Indi Molecular

Series A in 2017
Indi Molecular, Inc. is a life sciences company based in Culver City, California, established in 2013 as a spinout from Integrated Diagnostics. The company specializes in developing a synthetic class of diagnostic and therapeutic agents known as protein-catalyzed capture (PCC) agents. These agents possess antibody-like properties and are created through a collaborative process with the California Institute of Technology, utilizing a technique called click chemistry, which allows for precise and stable molecular assembly. PCCs are designed to offer improved selectivity and binding affinity compared to traditional monoclonal antibodies, along with a significantly lower molecular weight. This innovative approach enables PCCs to function both as precision-targeted therapeutics and as agents for in vivo PET imaging, utilizing a shared chelation chemistry platform to optimize their application in healthcare settings.

UniKey Technologies

Convertible Note in 2017
UniKey Technologies specializes in smart access control solutions. It offers a mobile platform that replaces traditional keys with smartphone-based electronic keys, featuring touch-to-open technology, intelligent detection of user location, and robust security measures. The company partners with lock manufacturers like Kwikset and Weiser to create smart locks such as Kevo, and provides cloud-based lock management for multifamily properties and commercial businesses.

Amygdala Neurosciences

Seed Round in 2017
Amygdala Neurosciences, Inc. is a biopharmaceutical company based in Palo Alto, California, dedicated to discovering, developing, and commercializing pharmacotherapies aimed at treating and preventing addiction. Incorporated in 2015, the company is focused on its lead product, ANS-6637, a selective and reversible aldehyde dehydrogenase 2 (ALDH2) inhibitor. This innovative compound is designed to prevent pathophysiologic dopamine surges that typically contribute to drug-seeking behavior, cravings, and relapse, without affecting baseline dopamine levels. Pre-clinical studies have shown that ANS-6637 effectively reduces self-administration and relapse in various models of substance use, including nicotine, alcohol, cocaine, heroin, and methamphetamine, and also exhibits anxiolytic properties. Having completed extensive Phase 1 studies, Amygdala Neurosciences is poised to initiate Phase 2 efficacy studies, with an initial focus on smoking cessation alongside parallel development for cocaine, opioid, and alcohol use disorders.

Thunder Industries

Series B in 2017
Thunder is a technology company that focuses on streamlining the advertising process through its Creative Management Platform. This platform enables advertisers to efficiently create, scale, and manage ad creatives across multiple devices and formats, including display, video, and native ads. By reducing creative friction, Thunder allows brands, media companies, and agencies to produce advertisements more rapidly and effectively. The platform features a user-friendly interface that caters to a range of users, from general marketers to advanced designers, providing tools for testing and targeting creatives to specific audiences across various channels. Thunder serves over 100 notable clients, including InterContinental Hotels Group, Time Warner Cable, Charter Communications, and Hearst, enhancing their advertising capabilities and reach.

Twist Bioscience

Venture Round in 2017
Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Freenome

Series A in 2017
Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Welkin Health

Series A in 2017
Founded in 2013, Welkin Health develops software that guides healthcare teams through patient management workflows. Its platform ensures patients receive care at the right time by configuring care programs into actionable tasks for health workers. Welkin's software facilitates communication between providers, health plans, and patients via phone, text, video, and email.

3T Biosciences

Convertible Note in 2017
Founded in 2017, 3T Biosciences is a biotechnology company based in Menlo Park, California. It specializes in immunotherapies for cancer treatment.

Womply

Series B in 2016
Womply is a local commerce platform founded in 2011 that aims to support the growth of small businesses in a digital environment. The company offers a range of applications, APIs, and marketing and financial tools designed to enhance local commerce for over 500,000 businesses across the United States. Womply's services are driven by its proprietary Womply Commerce Graph, a comprehensive data asset that provides insights into local commerce dynamics. The platform includes features for online presence and reputation management, as well as customer and revenue analytics, addressing the typical needs of local businesses. Through its technology and data-driven approach, Womply seeks to empower small businesses to thrive and simplify their operational challenges.

Mozio

Non Equity Assistance in 2016
Founded in 2012, Mozio operates an online platform that aggregates and compares various airport ground transportation options worldwide. Its services include shared ride shuttles, private vans, taxis, limousines, and public transit. Mozio enables travelers to search and book these services through its user-friendly interface, facilitating seamless travel from airports to final destinations.

InCarda Therapeutics

Venture Round in 2016
InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Evidation Health

Series B in 2016
Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

ViewPoint Therapeutics

Series A in 2016
ViewPoint Therapeutics, founded in 2014 and headquartered in San Francisco, specializes in developing treatments for diseases caused by protein misfolding. Its primary focus is on age-related cataracts, a leading cause of blindness worldwide. The company's innovative approach involves creating crystallin stabilizers, including a small molecule active in preclinical models of cataracts. These stabilizers aim to prevent or reverse protein misfolding, which underlies various common disorders associated with aging. ViewPoint Therapeutics is committed to advancing its pipeline to deliver effective therapies for these conditions.

Arterys

Series A in 2016
Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

SensOmics

Seed Round in 2016
SensOmics develops innovative medical wearable technology aimed at early detection of pediatric diseases. The company combines genomics with clinical informatics, electrical engineering, and artificial intelligence to enable healthcare professionals to diagnose and treat conditions more effectively.

Aegis Surgical

Series B in 2016
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

RallyPoint

Series B in 2015
RallyPoint Networks, Inc. is an online networking platform dedicated to serving current and former U.S. military members, as well as their civilian supporters. Founded in 2012 and based in Watertown, Massachusetts, RallyPoint facilitates connections among its two million users, enabling them to build professional networks and explore career opportunities both within the military and in the private sector. The platform assists members in translating their military experiences for civilian employers, effectively bridging the gap between transitioning veterans and organizations seeking their skills. RallyPoint aims to support the military community in leading successful and fulfilling lives while providing employers with targeted tools to engage with this unique talent pool. The company operates as a subsidiary of Student Veterans of America.

Welldoc

Series B in 2015
WellDoc, Inc. is a healthcare technology company focused on chronic disease management, particularly diabetes. Founded in 2005 and headquartered in Baltimore, Maryland, with additional offices in Wilmington, Delaware, and Bengaluru, India, WellDoc develops innovative solutions that integrate into existing healthcare workflows. Its flagship platform, DiabetesManager, provides personalized, real-time coaching and support for patients and healthcare providers, facilitating self-management and adherence to treatment regimens. The platform features tools for medication reminders, alerts for out-of-range metrics, and cloud-based analytics for tracking health outcomes. Additionally, WellDoc offers BlueStar, a mobile prescription therapy solution that guides patients in managing their diabetes. The company serves various stakeholders in the healthcare ecosystem, including payors, employers, pharmaceutical companies, and medical device firms, and has established strategic partnerships to enhance its offerings.

Profusa

Series B in 2015
Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the design and development of tissue-integrated sensors and biosensors aimed at improving diabetes management. Founded in 2009, the company focuses on creating biointegrated sensors that allow individuals to monitor their biochemical data in real-time, facilitating better management of personal health and chronic diseases. Profusa's technology aims to seamlessly integrate with the body, providing continuous, clinical-grade data that enhances health outcomes. In addition to its sensor technology, the company has developed software that offers biofeedback to support chronic disease management and promote healthy living.

Arterys

Series A in 2015
Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

Thunder Industries

Series B in 2015
Thunder is a technology company that focuses on streamlining the advertising process through its Creative Management Platform. This platform enables advertisers to efficiently create, scale, and manage ad creatives across multiple devices and formats, including display, video, and native ads. By reducing creative friction, Thunder allows brands, media companies, and agencies to produce advertisements more rapidly and effectively. The platform features a user-friendly interface that caters to a range of users, from general marketers to advanced designers, providing tools for testing and targeting creatives to specific audiences across various channels. Thunder serves over 100 notable clients, including InterContinental Hotels Group, Time Warner Cable, Charter Communications, and Hearst, enhancing their advertising capabilities and reach.

Welkin Health

Seed Round in 2015
Founded in 2013, Welkin Health develops software that guides healthcare teams through patient management workflows. Its platform ensures patients receive care at the right time by configuring care programs into actionable tasks for health workers. Welkin's software facilitates communication between providers, health plans, and patients via phone, text, video, and email.

Twist Bioscience

Series C in 2015
Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Thunder Industries

Venture Round in 2015
Thunder is a technology company that focuses on streamlining the advertising process through its Creative Management Platform. This platform enables advertisers to efficiently create, scale, and manage ad creatives across multiple devices and formats, including display, video, and native ads. By reducing creative friction, Thunder allows brands, media companies, and agencies to produce advertisements more rapidly and effectively. The platform features a user-friendly interface that caters to a range of users, from general marketers to advanced designers, providing tools for testing and targeting creatives to specific audiences across various channels. Thunder serves over 100 notable clients, including InterContinental Hotels Group, Time Warner Cable, Charter Communications, and Hearst, enhancing their advertising capabilities and reach.

Aegis Surgical

Convertible Note in 2015
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

Amygdala Neurosciences

Venture Round in 2015
Amygdala Neurosciences, Inc. is a biopharmaceutical company based in Palo Alto, California, dedicated to discovering, developing, and commercializing pharmacotherapies aimed at treating and preventing addiction. Incorporated in 2015, the company is focused on its lead product, ANS-6637, a selective and reversible aldehyde dehydrogenase 2 (ALDH2) inhibitor. This innovative compound is designed to prevent pathophysiologic dopamine surges that typically contribute to drug-seeking behavior, cravings, and relapse, without affecting baseline dopamine levels. Pre-clinical studies have shown that ANS-6637 effectively reduces self-administration and relapse in various models of substance use, including nicotine, alcohol, cocaine, heroin, and methamphetamine, and also exhibits anxiolytic properties. Having completed extensive Phase 1 studies, Amygdala Neurosciences is poised to initiate Phase 2 efficacy studies, with an initial focus on smoking cessation alongside parallel development for cocaine, opioid, and alcohol use disorders.

Evidation Health

Series A in 2014
Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

CardioGen Sciences

Seed Round in 2014
CardioGen Sciences is a biotechnology company that develops and offers gene therapy solutions for orphan-inherited arrhythmogenic diseases. It was founded in 2014 and is based in Palo Alto, California.

Womply

Venture Round in 2014
Womply is a local commerce platform founded in 2011 that aims to support the growth of small businesses in a digital environment. The company offers a range of applications, APIs, and marketing and financial tools designed to enhance local commerce for over 500,000 businesses across the United States. Womply's services are driven by its proprietary Womply Commerce Graph, a comprehensive data asset that provides insights into local commerce dynamics. The platform includes features for online presence and reputation management, as well as customer and revenue analytics, addressing the typical needs of local businesses. Through its technology and data-driven approach, Womply seeks to empower small businesses to thrive and simplify their operational challenges.

LiquidM Technology

Venture Round in 2014
LiquidM Technology, established in 2013, is a Berlin-based company that operates as a subsidiary of Smart AdServer SAS. It specializes in providing a single, intuitive platform for advertising and campaign management, primarily focused on mobile display media. The company's modular, cloud-based software enables agencies and trading desks to customize their ad tech infrastructure, offering greater efficiency, control, and insights into media planning and buying. LiquidM's platform is white-labeled, agnostic to third-party integrations, and supports real-time bidding, targeting, and inventory procurement.

CardioDx

Private Equity Round in 2014
CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Signal Vine

Seed Round in 2014
Signal Vine, Inc. is a technology company that specializes in developing an enterprise text messaging platform designed to enhance communication within educational and nonprofit sectors. Founded in 2013 and headquartered in Alexandria, Virginia, the company offers a range of features including targeted messaging, an intuitive interface, case management, and comprehensive reporting and analytics. By utilizing a blended messaging approach, Signal Vine enables its clients—such as K-12 schools, higher education institutions, nonprofits, and government programs—to leverage student data to deliver personalized communications. This capability aims to improve student engagement by sending timely reminders and support messages about important deadlines and opportunities, ultimately fostering better enrollment and retention outcomes. Additionally, Signal Vine provides customer support services to assist users in maximizing the effectiveness of their messaging strategies.

Biomimedica

Venture Round in 2014
Biomimedica is a medical device company based in South San Francisco, California, dedicated to innovating joint repair solutions through its proprietary synthetic cartilage technology. Founded in 2007, the company specializes in developing synthetic cartilages designed to restore the surface of damaged joints, providing effective medical devices for joint repair. Its pioneering approaches aim to enhance patient outcomes and advance the field of orthopedic medicine.

Benefitter Insurance Solutions

Debt Financing in 2014
Benefitter Insurance Solutions, Inc. is a company that provides web-based tools designed to assist employers in managing employee health coverage. Incorporated in 2012 and based in San Francisco, California, it offers a range of solutions including ReformCommunicator, which generates required communications regarding healthcare options; ReformNavigator, which assists employees in selecting and enrolling in health insurance; ReformAdvisor, which helps determine the suitability of employer-sponsored coverage; and ReformReadiness, which gathers necessary data for employee census and insurance quoting. By enhancing the decision-making process for both employers and employees, Benefitter aims to simplify navigation through health care reform and improve overall employee well-being. As of August 2015, the company operates as a subsidiary of HealthMarkets Insurance Company.

Twist Bioscience

Series B in 2014
Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Reify Health

Seed Round in 2014
Reify Health, Inc. is a Baltimore-based company that specializes in cloud-based software aimed at enhancing the development of new therapies within the life sciences sector. Founded in 2010, Reify Health provides solutions designed to streamline clinical research processes, particularly in the area of patient enrollment for clinical trials. Its flagship product, StudyTeam, allows research sponsors, contract research organizations, and clinical sites to achieve faster and more predictable enrollment outcomes. By automating and simplifying the enrollment process, Reify Health's software enables teams to concentrate on essential tasks that drive research success, thereby improving overall productivity and optimizing study budgets.

Aegis Surgical

Venture Round in 2014
Aegis Surgical Limited will facilitate less invasive placement of aortic valves compared to open heart surgery, on an out-patient basis.

Twist Bioscience

Series A in 2014
Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Maverix Biomics

Series A in 2014
Maverix Biomics, Inc. is a biotechnology company based in San Mateo, California, that offers a cloud-based platform tailored for biologists and life science researchers. Founded in 2010, the platform facilitates the management, analysis, and visualization of genomic data, addressing the needs of researchers in various domains, including RNA-seq, ChIP-seq, and methylation analysis. By integrating genomic data with biomic information across viral, bacterial, vertebrate, and plant genomes, Maverix Biomics aims to enhance research capabilities and foster collaborative discovery. The company leverages expertise from leading research institutions and technology firms, creating an open platform that combines advanced bioinformatics with user-friendly features to streamline complex data analytics. This approach not only accelerates scientific advancements but also helps overcome traditional research bottlenecks.

Womply

Venture Round in 2014
Womply is a local commerce platform founded in 2011 that aims to support the growth of small businesses in a digital environment. The company offers a range of applications, APIs, and marketing and financial tools designed to enhance local commerce for over 500,000 businesses across the United States. Womply's services are driven by its proprietary Womply Commerce Graph, a comprehensive data asset that provides insights into local commerce dynamics. The platform includes features for online presence and reputation management, as well as customer and revenue analytics, addressing the typical needs of local businesses. Through its technology and data-driven approach, Womply seeks to empower small businesses to thrive and simplify their operational challenges.

Indi Molecular

Seed Round in 2013
Indi Molecular, Inc. is a life sciences company based in Culver City, California, established in 2013 as a spinout from Integrated Diagnostics. The company specializes in developing a synthetic class of diagnostic and therapeutic agents known as protein-catalyzed capture (PCC) agents. These agents possess antibody-like properties and are created through a collaborative process with the California Institute of Technology, utilizing a technique called click chemistry, which allows for precise and stable molecular assembly. PCCs are designed to offer improved selectivity and binding affinity compared to traditional monoclonal antibodies, along with a significantly lower molecular weight. This innovative approach enables PCCs to function both as precision-targeted therapeutics and as agents for in vivo PET imaging, utilizing a shared chelation chemistry platform to optimize their application in healthcare settings.

RallyPoint

Series A in 2013
RallyPoint Networks, Inc. is an online networking platform dedicated to serving current and former U.S. military members, as well as their civilian supporters. Founded in 2012 and based in Watertown, Massachusetts, RallyPoint facilitates connections among its two million users, enabling them to build professional networks and explore career opportunities both within the military and in the private sector. The platform assists members in translating their military experiences for civilian employers, effectively bridging the gap between transitioning veterans and organizations seeking their skills. RallyPoint aims to support the military community in leading successful and fulfilling lives while providing employers with targeted tools to engage with this unique talent pool. The company operates as a subsidiary of Student Veterans of America.

LiquidM Technology

Series A in 2013
LiquidM Technology, established in 2013, is a Berlin-based company that operates as a subsidiary of Smart AdServer SAS. It specializes in providing a single, intuitive platform for advertising and campaign management, primarily focused on mobile display media. The company's modular, cloud-based software enables agencies and trading desks to customize their ad tech infrastructure, offering greater efficiency, control, and insights into media planning and buying. LiquidM's platform is white-labeled, agnostic to third-party integrations, and supports real-time bidding, targeting, and inventory procurement.

Lark

Venture Round in 2013
Lark is a developer of a virtual platform focused on chronic disease prevention and management. Founded in 2011 by Julia Hu and Jeff Zira, the company is headquartered in Mountain View, California. Lark's platform leverages advanced artificial intelligence alongside human coaching and connected devices to offer real-time, personalized support and counseling. This approach aims to help users make healthier choices and effectively manage their chronic conditions. The company's programs, including those recognized by the CDC for diabetes prevention, wellness, diabetes care, and hypertension, serve approximately 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in multiple peer-reviewed journals and analyst reports.

Profusa

Venture Round in 2013
Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the design and development of tissue-integrated sensors and biosensors aimed at improving diabetes management. Founded in 2009, the company focuses on creating biointegrated sensors that allow individuals to monitor their biochemical data in real-time, facilitating better management of personal health and chronic diseases. Profusa's technology aims to seamlessly integrate with the body, providing continuous, clinical-grade data that enhances health outcomes. In addition to its sensor technology, the company has developed software that offers biofeedback to support chronic disease management and promote healthy living.

Keepsafe

Series A in 2013
Keepsafe Software Inc. is a company that specializes in digital privacy solutions, providing applications designed to protect personal content on mobile devices. Founded in 2012 and based in San Francisco, California, Keepsafe offers a suite of apps, including Keepsafe Photos, Keepsafe Documents, and AppLock, which allow users to secure and manage their private photos, videos, and documents. The software is available for both iOS and Android platforms and is designed to prevent unauthorized access to sensitive data, enabling users to maintain ownership over their digital privacy while providing options for safe sharing. Keepsafe aims to simplify the management of personal information in the digital realm, making privacy as straightforward as it is in the physical world.

Arterys

Seed Round in 2013
Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

Evidation Health

Seed Round in 2013
Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

Synecor

Venture Round in 2013
Synecor LLC is a medical device company based in Durham, North Carolina, with additional locations in California and North Carolina. Founded in 2000 by Dr. Richard Stack, the company emerged from collaborative relationships in the field of interventional cardiology. Synecor specializes in developing innovative medical device technologies across various specialties, including obesity and spine therapeutics. The company focuses on creating minimally invasive device-based treatments, bioerodible vascular stent platforms for coronary artery disease, and solutions for managing arrhythmias. Additionally, Synecor is advancing a technology platform designed to access and treat the gastrointestinal system through natural orifices. By addressing unmet medical needs, Synecor aims to offer effective treatment options that enable patients to begin their care promptly, thereby improving the likelihood of successful outcomes.

HealthTap

Series B in 2013
HealthTap is a virtual-first healthcare provider that delivers affordable urgent and primary care services to all Americans, regardless of insurance status. The company aims to ensure equitable access to quality physician care across the nation. HealthTap's platform allows users to connect with doctors through various means, including limited texting, video appointments, and urgent care consultations with the next available physician. Additionally, the service offers free responses to health inquiries from a network of volunteer doctors across different specialties, empowering users to select and maintain a long-term primary care physician for their ongoing health needs.

Proteus Digital Health

Series F in 2013
Proteus Digital Health is a digital medicines company that developed technology to integrate medicines with ingestible sensors, wearable devices, mobile applications, and cloud-based data systems. Its digital health feedback technology provided insights into medication adherence and physiological responses, helping patients manage their health and enabling collaboration among caregivers and clinicians. The company offered ingestible sensors, wearable patches, and analytics portals to monitor patients remotely, improve therapy adherence, and enhance clinical outcomes, with data analytics supporting physicians and health systems in decision making. Founded in 2001 and based in Redwood City, California, it was formerly known as Proteus Biomedical.

Esperion

Venture Round in 2013
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Reify Health

Debt Financing in 2013
Reify Health, Inc. is a Baltimore-based company that specializes in cloud-based software aimed at enhancing the development of new therapies within the life sciences sector. Founded in 2010, Reify Health provides solutions designed to streamline clinical research processes, particularly in the area of patient enrollment for clinical trials. Its flagship product, StudyTeam, allows research sponsors, contract research organizations, and clinical sites to achieve faster and more predictable enrollment outcomes. By automating and simplifying the enrollment process, Reify Health's software enables teams to concentrate on essential tasks that drive research success, thereby improving overall productivity and optimizing study budgets.

Arterys

Seed Round in 2013
Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

CardioDx

Private Equity Round in 2012
CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Biomimedica

Series B in 2012
Biomimedica is a medical device company based in South San Francisco, California, dedicated to innovating joint repair solutions through its proprietary synthetic cartilage technology. Founded in 2007, the company specializes in developing synthetic cartilages designed to restore the surface of damaged joints, providing effective medical devices for joint repair. Its pioneering approaches aim to enhance patient outcomes and advance the field of orthopedic medicine.

Reify Health

Seed Round in 2012
Reify Health, Inc. is a Baltimore-based company that specializes in cloud-based software aimed at enhancing the development of new therapies within the life sciences sector. Founded in 2010, Reify Health provides solutions designed to streamline clinical research processes, particularly in the area of patient enrollment for clinical trials. Its flagship product, StudyTeam, allows research sponsors, contract research organizations, and clinical sites to achieve faster and more predictable enrollment outcomes. By automating and simplifying the enrollment process, Reify Health's software enables teams to concentrate on essential tasks that drive research success, thereby improving overall productivity and optimizing study budgets.

Terra Bella

Series C in 2012
Terra Bella is a private company based in Mountain View, California, specializing in high-resolution satellite imagery and analytics services. Originally founded as Skybox Imaging in 2009 by Dan Berkenstock, Julian Mann, John Fenwick, and Ching-Yu Hu, the company operates the SkySat-1 satellite, which captures detailed panchromatic and multispectral images of the Earth. Terra Bella focuses on analyzing the movement of goods and people, providing valuable visual data for various applications, including supply chain monitoring, shipping logistics, industrial plant activity, and humanitarian relief efforts. Through its advanced imaging technology, the company aims to deliver critical insights that support decision-making across multiple sectors.

Keepsafe

Seed Round in 2012
Keepsafe Software Inc. is a company that specializes in digital privacy solutions, providing applications designed to protect personal content on mobile devices. Founded in 2012 and based in San Francisco, California, Keepsafe offers a suite of apps, including Keepsafe Photos, Keepsafe Documents, and AppLock, which allow users to secure and manage their private photos, videos, and documents. The software is available for both iOS and Android platforms and is designed to prevent unauthorized access to sensitive data, enabling users to maintain ownership over their digital privacy while providing options for safe sharing. Keepsafe aims to simplify the management of personal information in the digital realm, making privacy as straightforward as it is in the physical world.

HealthTap

Series A in 2011
HealthTap is a virtual-first healthcare provider that delivers affordable urgent and primary care services to all Americans, regardless of insurance status. The company aims to ensure equitable access to quality physician care across the nation. HealthTap's platform allows users to connect with doctors through various means, including limited texting, video appointments, and urgent care consultations with the next available physician. Additionally, the service offers free responses to health inquiries from a network of volunteer doctors across different specialties, empowering users to select and maintain a long-term primary care physician for their ongoing health needs.

ICON Aircraft

Series C in 2011
ICON Aircraft, Inc. is a manufacturer based in Vacaville, California, that specializes in designing, developing, and producing light consumer sport aircraft. Founded in 2004, the company aims to make personal flight more accessible through innovative and safe aircraft, including its flagship model, the A5. The A5 is an amphibious sport plane recognized for its advanced aeronautical engineering, unique design, and safety features, including being the world's first production aircraft that is spin-resistant. ICON Aircraft also operates an online store selling various aviation-related gear and apparel. The company's mission is to democratize personal flight and 3-D mobility, fostering a culture that encourages intelligent risk-taking and collaboration among its team members. With a commitment to delivering technologically advanced and consumer-friendly products, ICON Aircraft seeks to inspire a global community of aviation enthusiasts.

HealthTap

Seed Round in 2011
HealthTap is a virtual-first healthcare provider that delivers affordable urgent and primary care services to all Americans, regardless of insurance status. The company aims to ensure equitable access to quality physician care across the nation. HealthTap's platform allows users to connect with doctors through various means, including limited texting, video appointments, and urgent care consultations with the next available physician. Additionally, the service offers free responses to health inquiries from a network of volunteer doctors across different specialties, empowering users to select and maintain a long-term primary care physician for their ongoing health needs.

Immunocellular Therapeutics

Venture Round in 2011
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company specializing in the development of immune-based therapies for various cancers. The company is known for its innovative products, including ICT-107, a dendritic cell immunotherapy designed for newly diagnosed glioblastoma multiforme, a highly aggressive brain cancer. Additionally, ImmunoCellular is advancing ICT-140, which targets tumor-associated antigens in ovarian cancer, and ICT-121, aimed at treating recurrent glioblastoma and other solid tumors by targeting CD133 markers on cancer stem cells. The company also explores Steam-to-T-Cell immunotherapies to enhance cancer treatment. ImmunoCellular Therapeutics has established licensing agreements with prestigious institutions such as the California Institute of Technology and The Johns Hopkins University. Originally named Optical Molecular Imaging, Inc., the company rebranded in November 2006 and is headquartered in Westlake Village, California.

Chimerix

Series F in 2011
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Ooma

Debt Financing in 2011
Ooma, Inc. is a communications services company that specializes in creating connected experiences for both businesses and consumers. Headquartered in Sunnyvale, California, Ooma offers a smart cloud-based software-as-a-service (SaaS) platform that provides a range of communication solutions. For businesses, Ooma delivers advanced voice and collaboration features through its offerings, such as Ooma Office and Ooma Enterprise, which include services like call recording, voicemail transcription, and mobile integration. For residential customers, Ooma provides home communications solutions like Ooma Telo, which serves as a primary phone line with high-definition voice quality and smart security features. The company also offers a variety of products, including mobile apps and security solutions, allowing users to monitor and control their home environments. Ooma generates revenue primarily through subscription services, distributing its products through direct sales, retailers, and online channels. Established in 2003, Ooma continues to innovate in the realm of connected communications and security.

Rapidscan Pharma Solutions

Series A in 2010
Rapidscan Pharma Solutions, Inc. is a pharmaceutical company founded in 2010, specializing in the development, manufacture, and sale of a pharmacological stress agent known as Regadenoson. This agent is utilized in the diagnosis and risk stratification of cardiovascular disease, particularly for patients undergoing myocardial perfusion imaging procedures. Rapidscan has secured licensing rights to market Regadenoson across various regions, including Europe, Latin America, Japan, Australia, New Zealand, and Israel. With a significant patient population affected by coronary artery disease, the company addresses a critical need in cardiovascular diagnostics. Rapidscan operates as a subsidiary of GE Healthcare.

Provade

Series F in 2010
Provade, Inc. is a provider of enterprise vendor management systems focused on workforce management and procurement. Established in 2004 and headquartered in Milwaukee, Wisconsin, with additional offices in Pleasanton, California; Highworth, United Kingdom; and Sydney, Australia, the company serves medium to large enterprises across various sectors, including technology, finance, and manufacturing. Provade specializes in contingent workforce management and offers a suite of services such as identity management, implementation, training, support, and managed services. Its solutions are built around Oracle's enterprise platform, enabling organizations to improve efficiency, gain visibility, and achieve measurable savings in contingent labor and procurement processes. The company also provides subscription-based applications that integrate with existing financial and HR systems, along with professional services to enhance procurement strategies. As of early 2018, Provade operates as a subsidiary of Smart ERP Solutions Inc.

CardioDx

Series D in 2010
CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

OfferIQ

Venture Round in 2010
OfferIQ specializes in providing paperless coupon services, focusing on delivering in-store shopping discounts directly to consumers' mobile phones. The company operates a Virtual Incentive Platform that links incentives to a consumer's debit or credit card, allowing these discounts to be redeemed seamlessly during the payment process. This approach eliminates the need for retailers to make any modifications at the point of sale or provide additional staff training.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.